HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.

Abstract
Spironolactone was first developed over 50 years ago as a potent mineralocorticoid receptor antagonist with undesirable side effects; it was followed a decade ago by eplerenone, which is less potent but much more mineralocorticoid receptor-specific. From a marginal role as a potassium-sparing diuretic, spironolactone has been shown to be an extraordinarily effective adjunctive agent in the treatment of progressive heart failure. Also, spironolactone is safe and protective in arterial hypertension, particularly in patients with so-called resistant hypertension. Eplerenone is the second oral aldosterone antagonist available for the treatment of arterial hypertension and heart failure. Treatment with eplerenone has been associated with decreased blood pressure and improved survival for patients with heart failure and reduced left ventricular ejection fraction. Due to the selectivity of eplerenone for the aldosterone receptor, severe adverse effects such as gynecomastia and vaginal bleeding seem to be less likely in patients who take eplerenone than in those who take spironolactone. The most common and potentially dangerous side effect of spironolactone--hyperkalemia--is also observed with eplerenone but the findings from clinical trials do not indicate more hyperkalemia induced drug withdrawals. Treatment with eplerenone should be initiated at a dosage of 25mg once daily and titrated to a target dosage of 50mg once daily preferably within 4 weeks. Serum potassium levels and renal function should be assessed prior to initiating eplerenone therapy, and periodic monitoring is recommended, especially in patients at high risk of developing hyperkalemia.
AuthorsMitja Lainscak, Francesco Pelliccia, Giuseppe Rosano, Cristiana Vitale, Michele Schiariti, Cesare Greco, Giuseppe Speziale, Carlo Gaudio
JournalInternational journal of cardiology (Int J Cardiol) Vol. 200 Pg. 25-9 (Dec 01 2015) ISSN: 1874-1754 [Electronic] Netherlands
PMID26404748 (Publication Type: Journal Article, Review)
CopyrightCopyright © 2015 Elsevier Ireland Ltd. All rights reserved.
Chemical References
  • Mineralocorticoid Receptor Antagonists
  • Spironolactone
  • Aldosterone
  • Eplerenone
Topics
  • Aldosterone (metabolism)
  • Drug Interactions
  • Eplerenone
  • Humans
  • Mineralocorticoid Receptor Antagonists (administration & dosage, adverse effects, pharmacology)
  • Randomized Controlled Trials as Topic
  • Spironolactone (administration & dosage, adverse effects, analogs & derivatives, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: